These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17932238)

  • 1. Temporary increases in problem behavior and sleep disruption following decreases in medication: a descriptive analysis of conditional rates.
    Rapp JT; Swanson G; Dornbusch K
    Behav Modif; 2007 Nov; 31(6):825-46. PubMed ID: 17932238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures.
    Zarcone JR; Hellings JA; Crandall K; Reese RM; Marquis J; Fleming K; Shores R; Williams D; Schroeder SR
    Am J Ment Retard; 2001 Nov; 106(6):525-38. PubMed ID: 11708938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of response to antidepressant medications.
    Langee HR; Conlon M
    Am J Ment Retard; 1992 Jul; 97(1):65-70. PubMed ID: 1497865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults.
    Khan BU
    J Autism Dev Disord; 1997 Aug; 27(4):479-89. PubMed ID: 9261670
    [No Abstract]   [Full Text] [Related]  

  • 5. Duration of risperidone treatment for BPSD.
    Snowdon J; Brodaty H; Ames D; Day S
    Int J Geriatr Psychiatry; 2006 Jul; 21(7):699-701. PubMed ID: 16821255
    [No Abstract]   [Full Text] [Related]  

  • 6. Sleep deprivation, allergy symptoms, and negatively reinforced problem behavior.
    Kennedy CH; Meyer KA
    J Appl Behav Anal; 1996; 29(1):133-5. PubMed ID: 8881356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study.
    Capone GT; Goyal P; Grados M; Smith B; Kammann H
    J Dev Behav Pediatr; 2008 Apr; 29(2):106-16. PubMed ID: 18349709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome.
    Pasini A; D'Agati E; Casarelli L; Curatolo P
    Brain Dev; 2010 May; 32(5):425-7. PubMed ID: 19428206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone-induced double incontinence.
    Hergüner S; Mukaddes NM
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1085-6. PubMed ID: 18387724
    [No Abstract]   [Full Text] [Related]  

  • 10. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
    Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buspirone for autistic disorder in a woman with an intellectual disability.
    Brahm NC; Fast GA; Brown RC
    Ann Pharmacother; 2008 Jan; 42(1):131-7. PubMed ID: 18056831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with reduction in antipsychotic medication dosage in adults with mental retardation.
    Luchins DJ; Dojka DM; Hanrahan P
    Am J Ment Retard; 1993 Jul; 98(1):165-72. PubMed ID: 8103998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis.
    Eckert EM; Dominick KC; Pedapati EV; Wink LK; Shaffer RC; Andrews H; Choo TH; Chen C; Kaufmann WE; Tartaglia N; Berry-Kravis EM; Erickson CA
    J Autism Dev Disord; 2019 Nov; 49(11):4595-4602. PubMed ID: 31468273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis.
    Zarcone JR; Lindauer SE; Morse PS; Crosland KA; Valdovinos MG; McKerchar TL; Matthew Reese R; Hellings JA; Schroeder SR
    Am J Ment Retard; 2004 Jul; 109(4):310-21. PubMed ID: 15176916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey.
    Unwin GL; Deb S
    Am J Ment Retard; 2008 Jan; 113(1):19-31. PubMed ID: 18173296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The treatment with tiparide of the agitation and aggressivity of oligophrenic patients (author's transl)].
    Garnier Y
    Sem Hop; 1978 Nov 8-15; 54(37-40):1149-50. PubMed ID: 33449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoxetine treatment of severe self-injury in young adults with mental retardation.
    Ricketts RW; Goza AB; Ellis CR; Singh YN; Singh NN; Cooke JC
    J Am Acad Child Adolesc Psychiatry; 1993 Jul; 32(4):865-9. PubMed ID: 8340311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease.
    Sharp SI; Ballard CG; Chen CP; Francis PT
    Am J Geriatr Psychiatry; 2007 May; 15(5):435-7. PubMed ID: 17463193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid risperidone in the treatment of psychotic agitation.
    Tsai C; Puzantian T
    CNS Drugs; 2002; 16(11):777; author reply 778. PubMed ID: 12383033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.